151 The incidence of thoracic re-irradiation at 3 UK cancer centres following curative intent radiotherapy for non-small cell lung cancerRadiotherapy planning and target volume delineation in lung cancer is lar
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Introduction:Lung cancer is a highly prevalent condition with non-small cell lung cancer (NSCLC), representing 80%. Given its high prevalence and poor survival rates, it is important to understand costs associated with NSCLC treatment.Objectives:To carry out an incidence-based study in three ...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screening of populations at risk with low-dose ...
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related mortality worldwide. Tumour ecosystems feature diverse immune cell types. Myeloid cells, in particular, are prevalent and have a well-established role in p
PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis. J Clin Med 2021;10:4583. [Crossref] [PubMed] Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis With Use of ...
We studied incidence, risk factors and prognostic impact of second primaries and other malignancies in patients with operated non-small cell lung cancer (NSCLC). Materials and Methods We retrospectively analysed 342 consecutive patients with curatively resected NSCLC between 2003 and 2007. Results 172 ...
Over the past decade, substantial progress has been made in the development of targeted and immune-based therapies for patients with advanced non-small-cell lung cancer. To further improve outcomes for patients with lung cancer, identifying and intercept
Metastatic disease is responsible for the majority of cancer-related deaths1. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 ...
British Journal of Cancer (2006) 94, 1927 – 1935 & 2006 Cancer Research UK All rights reserved 0007 – 0920/06 $30.00 www.bjcancer.com Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer BP Coe*,1,3, WW Lockwood1,3, L Girard2, R Chari1, C...